ArticleTechnology in cancer research & treatment
SMC3 Is Highly Expressed in Gliomas and Is Associated With Favorable Prognosis and B Cell-Related Immune Features.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionSMC3, a core component of the cohesin complex, plays diverse roles in tumorigenesis across different cancer types. However, its expression pattern, prognostic significance, and potential association with the immune microenvironment in gliomas remain largely unexplored.MethodsIn this retrospective study, we systematically analyzed SMC3 expression using multiple transcriptomic datasets, including CGGA (CGGA-325, CGGA-301), TCGA, and GEO (GSE4290, GSE50161), and validated protein-level expression in 44 clinical glioma specimens via immunohistochemistry. Associations with overall survival (OS) were assessed using Kaplan-Meier and Cox regression analyses. Immune microenvironment features were evaluated using ESTIMATE and TIMER2.0, and pathway enrichment was analyzed through GSEA. Core B cell-related genes and signaling pathways associated with SMC3 were further identified by intersecting SMC3-correlated genes with MSigDB C7 and KEGG B cell receptor signaling gene sets.ResultsSMC3 was significantly overexpressed in glioma tissues compared with normal brain, with higher expression in lower-grade gliomas (LGG) than glioblastoma (GBM). High SMC3 expression was associated with prolonged OS across CGGA-325, CGGA-301, and the Validation Cohort, and remained prognostically favorable in specific clinical subgroups, including MGMT-unmethylated and 1p/19q non-codeleted tumors. SMC3 high-expression tumors exhibited lower overall immune and stromal scores but showed significant positive correlations with B cell and plasma cell infiltration. GSEA revealed enrichment of PI3K-AKT-MYC- and MTORC1-related pathways in high SMC3 tumors. Intersection analyses identified four core B cell-related genes (AKT3, CHUK, GSK3B, PIK3CA) within the PI3K-Akt signaling pathway, suggesting SMC3 expression may be associated with B cell-related immune features.ConclusionsSMC3 is highly expressed in gliomas and is associated with favorable prognosis. Its expression correlates with B cell-related immune infiltration and activation of PI3K-Akt-MYC signaling, highlighting a potential role in shaping local immune microenvironments. These findings provide novel evidence for SMC3 as a prognostic biomarker and suggest a potential association with B cell-mediated immune features in gliomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.